Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions

Abstract

Optimal long-lasting treatment with sunitinib and sorafenib is limited by dose modifications (DMs) due to adverse events (AEs). These AEs may be underrecognized and their influence on health-related quality of life (HRQL) underestimated. Improved insight into the relationship between AEs and therapy decisions is needed. To improve decision making around… (More)
DOI: 10.1007/s00520-014-2223-2

Topics

6 Figures and Tables

Cite this paper

@article{Koldenhof2014SymptomsFT, title={Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions}, author={Josephine J Koldenhof and Petronella Els O Witteveen and Remco de Vos and Maudy Walraven and Corinne N Tillier and Henk M. W. Verheul and Saskia C C M Teunissen}, journal={Supportive Care in Cancer}, year={2014}, volume={22}, pages={2371-2380} }